Related content

In response to Isbister et al.: Application of pharmacokinetic–pharmacodynamic modeling in management of QT abnormalities after citalopram overdose

By Manini Alex   Smith Silas   Moskovitz Joshua   Nelson Lewis  

Intensive Care Medicine, Vol. 33, Iss. 4, 2007-04 ,pp. : 738-738

Springer Publishing Company

Access to resources Recommend Favorite

Reply to Dr. Mégarbane et al. regarding “Pharmacokinetic/pharmacodynamic modelling of cardiac toxicity in venlafaxine overdose”

By Isbister Geoffrey   Friberg Lena   Duffull Stephen  

Intensive Care Medicine, Vol. 33, Iss. 1, 2007-01 ,pp. : 197-197

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacokinetic/pharmacodynamic modelling of cardiac toxicity in venlafaxine overdose

By Mégarbane Bruno   Bloch Vanessa   Deye Nicolas   Baud Frédéric  

Intensive Care Medicine, Vol. 33, Iss. 1, 2007-01 ,pp. : 195-196

Springer Publishing Company

Access to resources Recommend Favorite

Population pharmacokinetic‐pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 91-2700, Iss. 11, 2015-11 ,pp. : 1236-1247

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacokinetic–pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA)

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 3, 2015-03 ,pp. : 328-335

John Wiley & Sons Inc

Access to resources Recommend Favorite